MTP19-01: T4 N0/N1 nonsmall cell lung cancer can be cured as a first line treatment with an expected five year survival rate as high as 43% provided a radical resection is performed  by Dartevelle, Philippe G. et al.
Copyright © 2007 by the International Association for the Study of Lung Cancer S285
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
A number of protein targets in these pathways possess dysregulated 
kinase activity, as a result of oncogenic gene mutation or overexpres-
sion, and play a pivotal role in carcinogenesis. Receptor tyrosine 
kinases with roles in proliferation - insulin-like growth factor-I recep-
tor, c-Met, and RET (rearranged during transfection); and cytoplasmic 
non-receptor kinases involved in proliferation and/or prevention of 
apoptosis - the serine/threonine kinases Raf, MEK, mTOR and Aurora 
kinases, and the tyrosine kinase Src. Met is a receptor tyrosine kinase 
widely expressed in epithelial and endothelial cells. Conversely, its 
cognate ligand HGF, is expressed by cells of the mesenchymal lineage, 
facilitating rigorous regulation of Met kinase activity. Activation and/or 
overexpression of Met have been widely documented as a frequent 
event in all major human tumor types Activating mutations of Met have 
been identiﬁed in hereditary and sporadic papillary renal carcinomas, 
in gastric, hepatocellular, head and neck, and ovarian carcinomas, and 
in small cell lung cancers and gliomas. Moreover, Met and/or HGF are 
commonly overexpressed in carcinomas and other solid tumors, and in 
their metastases. In clinical correlative studies, overexpression and/or 
dysregulation of Met and/or HGF is a negative prognostic indicator in 
patients with bladder, breast, cervical, gastric, head and neck, naso-
pharyngeal, thyroid, liver and lung carcinomas, and in patients with 
multiple myeloma and glioma. Twp inhibitors of MEK kinase, XL880 
and ARQ197 as well as an antibody against HGF, AMG102 have com-
pleted phase I trials and will be discussed. IGF-1R is another attractive 
target with 4 monoclonal antibodies targetin this receptor, IMC-A12, 
AMG 479, CP-751,871 and R1507 in the clinic. MEK inhibitors and 
src kinase inhibitors will also be discussed.
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Objective: T4 non-small cell lung carcinoma (NSCLC) is a particular 
group of locally advanced cancers especially when non associated with 
mediastinal lymph node involvement. During the past two decades, sur-
gical techniques for resecting locally advanced tumors [1-6] have been 
reﬁned, allowing consideration for curative surgical therapy in patients 
who would not previously have been considered operative candidates. 
Surgery on patients after induction therapy poses special perioperative 
risks and technical challenges, however. Also, controversy exists in giv-
ing neoadjuvant treatment for the patients who have locally advanced 
disease without mediastinal lymph node involvement. Patients with T4 
tumors with minimal nodal involvement (N0 or N1 disease) may ben-
eﬁt from surgery because these tumors are often more local-regionally 
than systemically aggressive. Survival rates of up to 30% to 40% have 
been reported for selected T4N0/N1 tumors.
The present report is aimed to assess operative mortality, morbidity, 
and long-term results of patients with surgically resected T4 NSCLC.
Methods: A retrospective analysis of survival characteristics in 271 
patients who underwent resection for T4 tumors between 1981- 2006 
was undertaken in a reference center for thoracic surgery. Patients were 
divided into four subgroups: 126 patients with superior sulcus tumors 
that were resected through anterior transclavicular approach, 92 with 
carinal involvement, 39 with massive superior vena cava (SVC) inva-
sion requiring graft interposition and 14 with the tumor invading medi-
astinum, heart, and great vessels (aorta, and proximal main pulmonary 
vessels). There were 221 (81.5%) men and 50 women with a mean age 
of 56.3 years (range, 31-80 years). Only a total of 75 (27.6%) patients 
underwent induction therapy. Lung resection consisted of 115 right 
pneumonectomies (42.4 %), 19 left pneumonectomies, 111 lobecto-
mies and 26 wedge resections. Among 126 patients with thoracic inlet 
tumors who had resection of lung, chest wall and subclavian vessels, 
35 underwent a combined “en bloc” resection of the ﬁrst thoracic verte-
brae at three or four levels associated with spinal ﬁxation. In the group 
of 39 SVC resections and prosthetic replacement, 17 patients required 
a combined right carinal pneumonectomy. Nine operations were per-
formed under cardiopulmonary bypass (CPB). Resection was complete 
in 249 (92%) patients. The pathologic N statuses were N0 in 114, N1 in 
94, N2 in 39, N3 in 17, and M1 in 7 patients. The histologic type was 
predominantly squamous cell carcinoma (n = 132; 48.7%). 139 (51.2%) 
patients received adjuvant therapy including radiation therapy in 109 
cases. Follow-up was complete for all patients.
Results: Overall thirty day mortality and morbidity rates were 4% and 
35%, respectively. Postoperative death occurred in 6 patients (6.5%) 
with carinal resection, one (0.8 %) with superior sulcus tumors, three 
(7.6 %) with SVC invasion, and one with invasion of the mediastinum 
(7.1 %). In univariate and multivariate analyses, only right pneumonec-
tomy (p=0.01) was associated with high rate of postoperative death. At 
follow-up, 185 patients are dead, whereas 86 patients are alive. Mean 
survival was 28 months. Overall 5-year survival rate was 38.4% (Fig-
ure 1). Survivals according to the four subgroups of T4 category were 
as follows: superior sulcus tumor, 36.6%; carinal involvement, 42.5%; 
SVC invasion, 29.7%; invasion of the mediastinum, 59.3%. Recurrenc-
es were observed in 138 patients of whom 29 were local and 15 were 
both local and systemic and 94 were systemic. By multivariate analysis, 
two factors signiﬁcantly and independently inﬂuenced survival: nodal 
status (N0-N1 vs. N2-3M1; p=0.003; 43% vs. 17.7% at 5 years, respec-
tively, ﬁgure 2), and complete resection (R0 vs. R1; p=0.01; 40.4% vs. 
15, 9%, respectively, ﬁgure 3).
Conclusions: Improved surgical techniques have increased the feasibil-
ity and radicality of extended operations for patients with potentially 
resectable but locally invasive NSCLC. Advances in the periopera-
tive management and postoperative care, along with a careful patient 
selection, will likely make the operative mortality and morbidity less 
prohibitive and a more favorable prognosis. 
It has been well demonstrated that the prognosis after operations for T4 
tumors mainly depends on the N stage and complete resection. Patients 
with N0 or minimal N1 disease and patients with complete resection do 
signiﬁcantly better after radical resection, a ﬁnding that clearly justiﬁes 
operative therapy in these patients. Presence of pN2 disease should 
be considered a potential contraindication to resection of T4 tumors. 
On the other hand, both the technical complexity of the operation and 
its rare occurrence therefore suggest centralization of the procedure 
to departments that express profound and continuous interest in such 
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problems and that at the same time have a high degree of experience 
with both general thoracic, cardiac, vascular and spinal procedures. 
Our policy regarding locally advanced lung cancer patients is to 
perform surgery on ﬁrst intention, whenever a complete resection is 
thought to be technically possible. Complete resection of T4 NSCLC 
results in 40.4% of 5-year survival rate. Patients with NSCLC who 
have carinal involvement, SVC invasion, superior sulcus tumor even 
with vertebral invasion or mediastinal invasion without mediastinal 
lymph node involvement should undergo radical surgery without any 
attempt of giving neoadjuvant chemotherapy. 
The thoracic medical and surgical community should promote all ef-
forts to extend the surgical indications for locally advanced NSCLC, 
making these operations available whenever possible to patients in 
whom radical resection can be achieved.
Figure 1.  Actuarial survival for patients with T4 Non-small Cell Lung Cancer 
undergoing resection, including the operative deaths. The estimated 5-, and 
10-year survivals were 38.4%, and 26%, respectively. A total of 73 patients 
were alive at 5 years, and 25 at 10 years.
Group N
Mortality 
n (%)
5 year 
survival (%)
N0/1 N2+ P
Superior Sulcus 
Tumor
126 1 (0.8%) 36.6 38.5 10.1 0.002
Carinal Invasion 92 6  (6.5%) 42.5 49.8 17.1 0.002
SVC Invasion* 39 3 (7.6%) 29.7 37.5 19.6 0.002
Mediastinal 
Invasion
14 1 (7.1%) 59.3 55.6 7.5 0.002
TOTAL 271 11 (4.05%) 38.4 43 17.7 0.002
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Image guided radiation therapy: the path to protons
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The goal of Image Guided Radiation Therapy (IGRT) is the delivery 
of higher doses to tumors without delivering as high doses to normal 
tissues or, conversely delivering the desired dose to the tumor and 
reducing the dose to normal tissues. IGRT is a term that has evolved 
over that last decade. This is exempliﬁed by the activities of the IGRT 
Committee of the Radiation Therapy Oncology Group which was 
established around that time. The ﬁrst focus was on 3-dimensional 
radiation therapy (3D CRT), a development that was fostered by grants 
from the National Cancer Institute in the 1980’s. These grants led to 
new tools that permitted 3-dimensional reconstructions of axial images 
from computed tomography and development of 3-dimensional radia-
tion dose distributions including heterogeneity corrections. Treatment 
planning systems (TPS) were developed in research institutions that 
stimulated industry to develop TPS: these became available between 
1993 and 1995. A grant from NCI led to creation of a reference and 
archival center at Washington University in St. Louis to which images 
could be sent and stored. This centered on 3D CRT for cancer of the 
prostate, but eventually expanded to other disease sites. Other reference 
centers developed and eventually coalesced into the Advanced Technol-
ogy Consortium (ATC) that serves as a resource for many forms of 
advanced radiation treatment technologies today. 
Physicists, engineers and equipment manufacturers developed the abil-
ity to plan and deliver intensity modulated radiation therapy (IMRT) 
whereby beamlets could be delivered with different intensities to 
shape radiation dose distributions even more precisely, giving higher 
doses to tumors and lesser doses to surrounding normal tissues. 3D 
CRT was adopted very quickly in the radiation oncology community 
whereas IMRT was greeted more skeptically. Reports of the successes 
of 3D CRT compared with traditional 2D treatments conﬁrmed the 
beneﬁt ﬁrst demonstrated in comparative treatment planning studies. 
Randomized trials showed improved outcomes both in higher tumor 
control probabilities and lower normal tissue effects. Single institution 
trials with IMRT have shown it possible to increase total doses even to 
higher levels than with 3D CRT with very low complication rates. Re-
cent results (non randomized) have demonstrated decreased pulmonary 
toxicity using IMRT for cancer of the lung compared with 3D CRT. 
IGRT now encompasses advanced techniques of patient immobilization 
and veriﬁcation (orthogonal images prior to treatment each day com-
pared with images from treatment planning). Means of imaging tumors 
after patients are positioned have been developed with ultrasound and 
CT. Methods of coping with tumor motion between and during treat-
ments have been implemented including 4d CT (capturing the images 
of the tumor while breathing, for example), respiratory gating, and 
ﬂuoroscopic tracking of ﬁducial markers near the tumor as the most 
sophisticated form of gating.
The lessons learned from improved tumor control and normal tissue 
avoidance with 3D CRT and IMRT support the continued evolution of 
